Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 8,850 KRW
Change Today +40.00 / 0.45%
Volume 38.4K
086890 On Other Exchanges
Symbol
Exchange
KOSDAQ
As of 1:14 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

isu abxis co ltd (086890) Snapshot

Open
8,900
Previous Close
8,810
Day High
8,960
Day Low
8,770
52 Week High
07/6/15 - 14,400
52 Week Low
11/27/14 - 5,944
Market Cap
132.6B
Average Volume 10 Days
161.9K
EPS TTM
-801.00
Shares Outstanding
15.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ISU ABXIS CO LTD (086890)

Related News

No related news articles were found.

isu abxis co ltd (086890) Related Businessweek News

No Related Businessweek News Found

isu abxis co ltd (086890) Details

ISU Abxis Co., Ltd. operates as a biopharmaceutical company worldwide. It provides pharmaceutical products for the treatment of cancer, and autoimmune and rare diseases. The company’s products include Clotinab, a monoclonal antibody injection that binds to the GPllb/llla of the glycoprotein of the human platelets; and Abcertin and Fabagal, which are orphan drug injections for enzyme replacement therapy for Gaucher's and Fabry's diseases. It is also involved in the research and development of products for the treatment of metastatic breast cancer, rheumatoid arthritis, hard-to-treat cancer, and hemophilia diseases. The company is headquartered in Seongnam, South Korea. ISU Abxis Co., Ltd. is a subsidiary of ISU Chemical Co., Ltd.

isu abxis co ltd (086890) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

isu abxis co ltd (086890) Key Developments

ISU ABXIS Co., Ltd. Proposes Changes to the Articles of Incorporation

ISU ABXIS Co., Ltd. proposed changes to the articles of incorporation which will be considered for approval at the AGM to be held on March 20, 2015.

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 20, 2015

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 20, 2015., at 09:00 Korea Standard Time. Location: global R & D center C-dong Corporation completed. Agenda: To approve audit report, sales report, external audit and financial statements (appropriation statement included); to approve changes to the articles of incorporation; to approve appointment of non emergency outside director; and to approve director remuneration.

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 21, 2014

ISU ABXIS Co., Ltd., Annual General Meeting, Mar 21, 2014., at 09:00 Korea Standard Time. Location: Pan-gyo is 712 Bundang Great beongil 22 C global R & D center.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
086890:KS 8,850.00 KRW +40.00

086890 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 086890.
View Industry Companies
 

Industry Analysis

086890

Industry Average

Valuation 086890 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 15.4x
Price/Book 7.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 16.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ISU ABXIS CO LTD, please visit www.abxis.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.